Biogen has appointed Paul McKenzie, PhD, as executive vice president, pharmaceutical operations & technology, effective July 1, 2016. He will report to George A. Scangos, chief executive officer, and will be a member of the Biogen management team. Dr. McKenzie was promoted from his previous position as senior vice president of global biologics manufacturing and technical operations.

Dr. McKenzie will lead the organization responsible for asset management, technical development, global manufacturing , supply chain operations, quality, and engineering . He will also oversee construction and operation of Biogen's advanced biologics manufacturing facility in Solothurn, Switzerland. He replaces John Cox, who last month was named chief executive officer of a new Biogen spin-off company dedicated to advancing treatments for hemophilia.

Dr. McKenzie joined Biogen in February from Johnson & Johnson, where he held a variety of leadership roles, most recently as vice president of R&D for J&J's Ethicon business. Prior to that role, Dr. McKenzie led the manufacturing and technical operations team responsible for internal and external manufacturing of Janssen's pharmaceutical portfolio. He also ran global development for Janssen R&D, helping to manage pipeline activities from discovery through clinical development and commercialization. Dr. McKenzie also held various R&D and manufacturing positions at Bristol-Myers Squibb and Merck.

Source: Biogen